| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Medicare’s expansion of coverage for A1c for diabetes screening in 2024 was followed by significant increases in use of the test and detection of prediabetes, new data showed. The researchers compared laboratory data from Quest Diagnostics from January 1, 2022, to September 30, 2023, with data from the same period in 2024-2025. “This is the first study I’m aware of that specifically looks at how the testing patterns changed after Medicare adopted the rule,” said co-investigator Jason Ng, MD, clinical professor of medicine in the Division of Endocrinology and Metabolism at the University of Pittsburgh Medical Center in Pittsburgh.
Cardiologist Dr. Marc Penn joins Good Day DC. to discuss how new, advanced testing can reveal hidden cardiovascular risks that standard cholesterol panels often overlook.
Now, for the first time, you can test your biological age when you get your next round of blood work. Humanity Health Inc. and Quest Diagnostics are launching “Humanity Biological Age.” This test is available in the U.S. via questhealth.com. It’s a $29 add-on to certain existing Quest blood panels (like the Elite Health Profile or Men’s/Women’s Comprehensive Health Profiles) with no extra blood draw needed.
More than 860 North Carolinians have tested positive for Cyclospora this summer. They join thousands of Americans nationwide testing positive for the parasite at levels the country has never seen before. Two North Carolina cases have now been tied to a multistate outbreak involving shredded lettuce. A Cyclospora diagnosis requires a stool sample. In North Carolina, many of those samples during this summer’s historic rise in cases have been sent to Quest Diagnostics. “It’s been a busy summer, to say the least,” said Dr. Ann MacIntyre, senior medical director for infectious diseases at Quest Diagnostics.
Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. On a laboratory table that normally sits empty, hundreds of feces samples are arranged in stacks six vials high. They’ve traveled by ground and plane, across seven different eastern U.S. states, for one purpose: to be tested for parasites, including cyclospora. And they’re coming faster than scientists here can test them. At Quest’s Clifton lab, workers are putting in extra hours.
Women with vaginosis are around three times as likely to also test positive for gonorrhea, chlamydia or other bacterial sexually transmitted infections, a new study says. The study results confirm guidance from the U.S. Centers for Disease Control and Prevention that women being treated for bacterial vaginosis should be tested for STIs, which can present with similar symptoms, researchers said in the journal O&G Open. "STIs can lead to serious reproductive and other health complications when left undetected and untreated,” senior researcher Dr. Damian Alagia said in a news release.
Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.'
As the liquid biopsy space has exploded in recent years, clinical laboratories are struggling to find sufficient staff to oversee and run these assays. "The problem is real," agreed Thomas Koch, senior VP and global head of research and development at Quest Diagnostics, adding that liquid biopsy "is a very fast-growing field with many players." Beyond the rise in demand for testing, test complexity has also contributed to the workforce shortage. Liquid biopsy tests often feature workflows involving dozens of steps along with sophisticated chemistries, hardware, software, and data analysis tools. "It's an entire ecosystem that is a little different from the standard clinical laboratory where you do, say, a calcium test, and then report it out," said Quest's Koch.
Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped the company beat second-quarter estimates. Shares of the New Jersey-based company rose about 5% in premarket trading following the results. Demand for the company's diagnostic testing services was strong across its physician, hospital and consumer channels, Quest said. The results were "well above what was widely expected," Barclays analysts said.
Framing sexually transmitted infections (STIs) as a large-scale problem often obscured by percentages, Damian Alagia, III, MD, MS, MBA, FACS, Chief, Hospital and Health Systems, and Senior Medical Director, Advanced Diagnostics / Women's Health, Quest Diagnostics, argued that universal, non-judgmental testing is central to reaching reproductive-age women. Alagia said absolute figures convey the scale more effectively than rates, noting over 1.5 million patients annually with chlamydial infections, some 190,000 patients with syphilis, and nearly 4,000 babies with congenital syphilis, in 2024 data from the Centers for Disease Control and Prevention (CDC).